Paper15057741
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Shiffman ML and 14 others. Gastroenterology, 2004. Cited by 363 papers, by iCite.
Cite this record
ConductScience Library. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Papers, record 15057741. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15057741
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepatitis C, Chronic | Major topic |
| Interferon-alpha | Major topic |
| Polyethylene Glycols | Major topic |
| Ribavirin | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Interferon alpha-2 | |
| Liver Cirrhosis | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Recombinant Proteins | |
| Treatment Failure |
Source PubMed
Grants19
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| M01RR-00042 | NCRR NIH HHS | United States | M01RR000042 | PubMed and NIH | NIH RePORTER |
| M01RR-00043 | NCRR NIH HHS | United States | M01RR000043 | PubMed and NIH | NIH RePORTER |
| M01RR-00051 | NCRR NIH HHS | United States | M01RR000051 | PubMed and NIH | NIH RePORTER |
| M01RR-00065 | NCRR NIH HHS | United States | M01RR000065 | PubMed and NIH | NIH RePORTER |
| M01RR-00633 | NCRR NIH HHS | United States | M01RR000633 | PubMed and NIH | NIH RePORTER |
| M01RR-00827 | NCRR NIH HHS | United States | M01RR000827 | PubMed and NIH | NIH RePORTER |
| M01RR-01066 | NCRR NIH HHS | United States | M01RR001066 | PubMed and NIH | NIH RePORTER |
| M01RR-06192 | NCRR NIH HHS | United States | M01RR006192 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2318 | NIDDK NIH HHS | United States | N01DK092318 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2319 | NIDDK NIH HHS | United States | N01DK092319 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2320 | NIDDK NIH HHS | United States | N01DK092320 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2321 | NIDDK NIH HHS | United States | N01DK092321 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2322 | NIDDK NIH HHS | United States | N01DK092322 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2323 | NIDDK NIH HHS | United States | N01DK092323 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2324 | NIDDK NIH HHS | United States | N01DK092324 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2325 | NIDDK NIH HHS | United States | N01DK092325 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2326 | NIDDK NIH HHS | United States | N01DK092326 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2327 | NIDDK NIH HHS | United States | N01DK092327 | PubMed and NIH | NIH RePORTER |
| N01-DK-9-2328 | NIDDK NIH HHS | United States | N01DK092328 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00491179 | Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin | Background |
Source ClinicalTrials.gov
Cited by108
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 363 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41157571 | Oncogenic Viruses in Organ Transplantation: Implications of Virus-Host Interactions for Cancer Development. | Viruses | 2025 | https://conductscience.org/library/papers/41157571 | PubMed |
| 36125059 | Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. | J Manag Care Spec Pharm | 2022 | https://conductscience.org/library/papers/36125059 | PubMed |
| 35626332 | Perceived Stress in Hepatitis C Virus Infected Patients under the DAA-Based Therapy. | Diagnostics (Basel) | 2022 | https://conductscience.org/library/papers/35626332 | PubMed |
| 32764876 | Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. | Drug Des Devel Ther | 2020 | https://conductscience.org/library/papers/32764876 | PubMed |
| 28469364 | Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. | Ann Gastroenterol | 2017 | https://conductscience.org/library/papers/28469364 | PubMed |
| 28232944 | Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment. | Biomed Res Int | 2017 | https://conductscience.org/library/papers/28232944 | PubMed |
| 27882182 | Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion. | Exp Ther Med | 2016 | https://conductscience.org/library/papers/27882182 | PubMed |
| 27832143 | Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. | PLoS One | 2016 | https://conductscience.org/library/papers/27832143 | PubMed |
| 27377910 | Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. | Clin Mol Hepatol | 2016 | https://conductscience.org/library/papers/27377910 | PubMed |
| 27246107 | Evidence-based clinical practice guidelines for liver cirrhosis 2015. | J Gastroenterol | 2016 | https://conductscience.org/library/papers/27246107 | PubMed |
| 27044763 | KASL clinical practice guidelines: management of hepatitis C. | Clin Mol Hepatol | 2016 | https://conductscience.org/library/papers/27044763 | PubMed |
| 26629360 | Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis. | BMJ Open Gastroenterol | 2015 | https://conductscience.org/library/papers/26629360 | PubMed |
| 26342813 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. | Curr Gastroenterol Rep | 2015 | https://conductscience.org/library/papers/26342813 | PubMed |
| 26201405 | APASL consensus statements and management algorithms for hepatitis C virus infection. | Hepatol Int | 2012 | https://conductscience.org/library/papers/26201405 | PubMed |
| 26185714 | Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. | Balkan Med J | 2015 | https://conductscience.org/library/papers/26185714 | PubMed |
| 25914454 | Management of hepatitis C infection before and after liver transplantation. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/25914454 | PubMed |
| 25755575 | Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India. | J Clin Exp Hepatol | 2014 | https://conductscience.org/library/papers/25755575 | PubMed |
| 25032178 | KASL clinical practice guidelines: management of hepatitis C. | Clin Mol Hepatol | 2014 | https://conductscience.org/library/papers/25032178 | PubMed |
| 24886378 | Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. | Trials | 2014 | https://conductscience.org/library/papers/24886378 | PubMed |
| 24834289 | Evaluated outcomes in patients with Chronic Hepatitis C. | Gastroenterol Hepatol Bed Bench | 2013 | https://conductscience.org/library/papers/24834289 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15057741
GET https://conductscience.org/api/papers/v1/15057741/cited_by?page=2